{
    "clinical_study": {
        "@rank": "30307", 
        "brief_summary": {
            "textblock": "This is an open label study to determine the effects of the administration of\n      Interferon-gamma on the clinical condition and immune function of patients with severe,\n      treatment refractory non-tuberculosis mycobacterial infections.  The study drug (interferon\n      gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year.\n      We may also collect blood from the relatives of these patients and normal volunteers in\n      order to characterize the genetic basis, if any, of our patients' disorders."
        }, 
        "brief_title": "Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma", 
        "completion_date": "November 2000", 
        "condition": [
            "Healthy", 
            "Mycobacterium Infections, Atypical"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mycobacterium Infections", 
                "Mycobacterium Infections, Atypical"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label study to determine the effects of the administration of\n      Interferon-gamma on the clinical condition and immune function of patients with severe,\n      treatment refractory non-tuberculosis mycobacterial infections.  The study drug (interferon\n      gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year.\n      We may also collect blood from the relatives of these patients and normal volunteers in\n      order to characterize the genetic basis, if any, of our patients' disorders."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary.\n\n        Received medical treatment for at least 3 months without improvement.\n\n        Preserved renal, hepatic and hematologic function.\n\n        Negative pregnancy urine and effective contraceptive.\n\n        Age range greater than 5.\n\n        No secondary immunodeficiency such as HIV or malignancy.\n\n        Not currently receiving cytotoxic therapy within the past 3 months.\n\n        Not pregnant or lactating.\n\n        No seizure disorders.\n\n        No known symptomatic cardiac disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001318", 
            "org_study_id": "920255", 
            "secondary_id": "92-I-0255"
        }, 
        "intervention": {
            "intervention_name": "interferon gamma", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "Immune Adjuvant", 
            "Phagocytes", 
            "Non-tuberculous Mycobacterial Infection"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "3086725", 
                "citation": "Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986 Jul 3;315(1):6-15."
            }, 
            {
                "PMID": "3880852", 
                "citation": "Horsburgh CR Jr, Mason UG 3rd, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore). 1985 Jan;64(1):36-48. Review."
            }, 
            {
                "PMID": "7908719", 
                "citation": "Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, Gallin JI. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med. 1994 May 12;330(19):1348-55."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001318"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1992", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1999"
    }, 
    "geocoordinates": {
        "National Institute of Allergy and Infectious Diseases (NIAID)": "38.985 -77.095"
    }
}